First-line doxorubicin and high-dose ifosfamide (DHI) in advanced soft tissue sarcoma (STS) patients. A phase II study of the Spanish Group for Research on Sarcomas (GEIS)

被引：0
|
作者：
Lopez-Pousa, A [1 ]
Montalar, J [1 ]
Buesa, J [1 ]
Maurel, J [1 ]
Martin, J [1 ]
Cassinello, J [1 ]
Sevilla, I [1 ]
de las Penas, R [1 ]
Cruz, J [1 ]
Balana, C [1 ]
机构：
[1] Hosp Sant Pau, Spanish Grp Res Sarcomas, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
564P
引用
收藏
页码：117 / 117
页数：1
相关论文
共 50 条
  • [31] Dose-intensive first-line chemotherapy with epirubicin and continuous infusion ifosfamide in adult patients with advanced soft tissue sarcomas: a phase II study
    Palumbo, R
    Neumaier, C
    Cosso, M
    Bertero, G
    Raffo, P
    Spadini, N
    Valente, S
    Villani, G
    Pastorino, M
    Toma, S
    EUROPEAN JOURNAL OF CANCER, 1999, 35 (01) : 66 - 72
  • [32] Sintilimab, doxorubicin and ifosfamide (AI) as first-line treatment in patients with advanced soft tissue sarcoma: A single-arm phase
    Luo, Z.
    Liu, X.
    Zhang, X.
    He, X.
    Zhang, S.
    Yan, W.
    Chen, Y.
    Wang, C.
    Xu, Y.
    Yu, L.
    Wang, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S1401 - S1401
  • [33] Radiologist review versus group peer review of claimed responses in a phase II study on high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the EORTC Soft Tissue and Bone Sarcoma Group
    Gwyther, SJ
    Nielsen, OS
    Judson, IR
    van Glabbeke, M
    Verweij, J
    ANTI-CANCER DRUGS, 2000, 11 (06) : 433 - 437
  • [34] Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An EORTC Soft Tissue and Bone Sarcoma Group randomized phase II study.
    Gelderblom, H.
    Blay, J.
    Seddon, B. M.
    Leahy, M.
    Ray-Coquard, I. L.
    De Brauwer, A.
    Veyt, E.
    Weitman, S. D.
    Hogendoorn, P. C.
    Hohenberger, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [35] Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas
    Palumbo, R
    Palmeri, S
    Antimi, M
    Gatti, C
    Raffo, P
    Villani, G
    Toma, S
    ANNALS OF ONCOLOGY, 1997, 8 (11) : 1159 - 1162
  • [36] Optimizing Clinical Care in Patients with Advanced Soft Tissue Sarcoma: A Phase II Study of a New Schedule of High-Dose Continuous Infusion Ifosfamide and Doxorubicin Combination
    De Pas, T.
    Rosati, G.
    Spitaleri, G.
    Boni, C.
    Tucci, A.
    Frustaci, S.
    Scalamogna, R.
    Radice, D.
    Boselli, S.
    Toffalorio, F.
    Catania, C.
    Noberasco, C.
    Delmonte, A.
    Vecchio, F.
    de Braud, F.
    CHEMOTHERAPY, 2011, 57 (03) : 217 - 224
  • [37] A phase II study of a new formulation of nonpegylated liposomal doxorubicin (doxorubicin GP-pharm) as first-line treatment in patients with advanced soft-tissue sarcomas (STS) who are age 65 or older: A GEIS trial.
    Lopez-Pousa, A.
    Nguyen, B. Bui
    Garcia del Muro, X.
    Martin Broto, J.
    Balana, C.
    Lavernia, J.
    Cruz, J.
    Maurel, J.
    Andres, R.
    Valverde, C. M.
    Fra, J.
    Martinez-Trufero, J.
    Lopez-Martin, J. A.
    Sevilla, I.
    Cubedo, R.
    Blay, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [38] Standard-dose doxorubicin versus sequential dose-dense doxorubicin and ifosfamide in patients with untreated advanced soft tissue sarcoma (ASTS): A GEIS Study
    Maurel, J.
    Lopez-Pousa, A.
    de las Penas, R.
    Fra, J.
    Cruz, J.
    Martin, J.
    Casado, A.
    Martinez-Trufero, J.
    Poveda, A.
    Garcia del Muro, X.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [39] DOXORUBICIN VERSUS CYVADIC VERSUS DOXORUBICIN PLUS IFOSFAMIDE IN FIRST-LINE TREATMENT OF ADVANCED SOFT-TISSUE SARCOMAS - A RANDOMIZED STUDY OF THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER SOFT-TISSUE AND BONE SARCOMA GROUP
    SANTORO, A
    TURSZ, T
    MOURIDSEN, H
    VERWEIJ, J
    STEWARD, W
    SOMERS, R
    BUESA, J
    CASALI, P
    SPOONER, D
    RANKIN, E
    KIRKPATRICK, A
    VANGLABBEKE, M
    VANOOSTEROM, A
    JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (07) : 1537 - 1545
  • [40] Combination of Pegylated Liposomal Doxorubicin (PLD) and ifosfamide (IFO) in patients with advanced soft tissue sarcoma (STS). A phase II study of the Hellenic Cooperative Oncology Group
    Bafaloukos, Dimitrios
    Kosmidis, Paris
    Briasoulis, Evangelos
    Gogas, Helen
    Aravantinos, Gerasimos
    Papadimitriou, Christos
    Economopoulos, Theofanis
    Papakostas, Pavlos
    Fountzilas, George
    ANNALS OF ONCOLOGY, 2004, 15 : 198 - 198
12345